Table 1.
Characteristics of 37,527 men diagnosed with prostate cancer between 1998 and 2011, and 357,384 cancer-free men from the background population.
| Prostate cancer with prior depression n = 3813 |
Prostate cancer without prior depression n = 33,714 |
All men with prostate cancer n = 37,527 |
Cancer-free men n = 357,384 |
|||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Suicide* rate, events per 100,000 PYRS | 121 | 38 | 45 | 40 | ||||
|
| ||||||||
| Median follow-up time, years (IQR) ** | 5.7 (2.4–8.1) | 6.3 (3.3–8.9) | 6.2 (3.1–8.8) | 8.4 (5.6–11.7) | ||||
|
| ||||||||
| Person-years at risk | 21,462 | 216,177 | 237,639 | 3,084,849 | ||||
|
| ||||||||
| Median age at diagnosis/index date, years (IQR) | 72 (65–79) | 71 (65–77) | 71 (65–77) | 68 (62–75) | ||||
|
| ||||||||
| n | (%) | n | (%) | n | (%) | n | (%) | |
|
| ||||||||
| Calendar period | ||||||||
| 1998–2002 | 824 | (22) | 7516 | (22) | 8340 | (22) | 131,339 | (37) |
| 2003–2007 | 1453 | (38) | 12,646 | (38) | 14,099 | (38) | 131,981 | (37) |
| 2008–2011 | 1536 | (40) | 13,552 | (40) | 15,088 | (40) | 94,064 | (26) |
|
| ||||||||
| Educational level | ||||||||
| Short (<9 years) | 1055 | (28) | 9125 | (27) | 10,180 | (27) | 101,202 | (28) |
| Medium (9–12 years) | 1631 | (43) | 14,404 | (43) | 16,035 | (43) | 152,178 | (43) |
| Long (>12 years) | 706 | (19) | 6969 | (21) | 7675 | (21) | 61,971 | (17) |
| Missing | 421 | (11) | 3216 | (10) | 3637 | (10) | 42,033 | (12) |
|
| ||||||||
| Disposable income, quintiles | ||||||||
| 1 (lowest) | 810 | (21) | 5815 | (17) | 6625 | (18) | 68,043 | (19) |
| 2 | 783 | (21) | 6533 | (19) | 7316 | (20) | 73,318 | (21) |
| 3 | 798 | (21) | 7291 | (22) | 8089 | (22) | 72,410 | (20) |
| 4 | 716 | (19) | 7466 | (22) | 8182 | (22) | 71,808 | (20) |
| 5 (Highest) | 705 | (19) | 6608 | (20) | 7313 | (20) | 71,780 | (20) |
| Missing | 1 | (0) | 1 | (0) | 2 | (0) | 0 | (0) |
|
| ||||||||
| Cohabitation status | ||||||||
| Living with a partner | 2599 | (68) | 25,897 | (77) | 28,496 | (76) | 263,599 | (74) |
| Living alone | 1214 | (32) | 7817 | (23) | 9031 | (24) | 93,785 | (26) |
|
| ||||||||
| Charlson comorbidity index | ||||||||
| 0 | 2354 | (62) | 26,103 | (77) | 28,457 | (76) | 276,388 | (77) |
| 1 | 931 | (24) | 5531 | (16) | 6463 | (17) | 56,462 | (16) |
| 2+ | 528 | (14) | 2079 | (6) | 2607 | (7) | 24,534 | (7) |
|
| ||||||||
| Median PSA at diagnosis, ng/ml (IQR) | 19.0 (9.1–59.3) | 19.0 (8.8–64.0) | 19.0 (8.8–63.0) | |||||
|
| ||||||||
| Gleason Score | ||||||||
| ≤6 | 1181 | (31) | 10,456 | (31) | 11,637 | (31) | ||
| 7 | 1246 | (33) | 11,001 | (33) | 12,247 | (33) | ||
| ≥8 | 1192 | (31) | 10,497 | (31) | 11,689 | (31) | ||
| Missing | 194 | (5) | 1760 | (5) | 1954 | (5) | ||
|
| ||||||||
| Clinical T stage at diagnosis | ||||||||
| T1 | 828 | (22) | 7031 | (21) | 7859 | (21) | ||
| T2 | 746 | (20) | 6718 | (20) | 7464 | (20) | ||
| T3 | 698 | (18) | 6339 | (19) | 7037 | (19) | ||
| T4 | 89 | (2) | 712 | (2) | 801 | (2) | ||
| Tx | 50 | (1) | 438 | (1) | 488 | (1) | ||
| Missing | 1402 | (37) | 12,476 | (37) | 13,878 | (37) | ||
|
| ||||||||
| N status | ||||||||
| N0 | 711 | (19) | 7105 | (21) | 7816 | (21) | ||
| N1 | 132 | (3) | 1242 | (4) | 1374 | (4) | ||
| Nx | 1568 | (41) | 12,891 | (38) | 14,459 | (39) | ||
| Missing | 1402 | (37) | 12,479 | (37) | 13,878 | (37) | ||
|
| ||||||||
| M status | ||||||||
| M0 | 1080 | (28) | 10,551 | (31) | 11,631 | (31) | ||
| M1 | 371 | (10) | 2911 | (9) | 3282 | (9) | ||
| Mx | 960 | (25) | 7776 | (23) | 8736 | (23) | ||
| Missing | 1402 | (37) | 12,476 | (37) | 13,878 | (37) | ||
|
| ||||||||
| Pre-TNM (WHO) stage | ||||||||
| Localized | 371 | (10) | 3512 | (10) | 3883 | (10) | ||
| Locally advanced | 66 | (2) | 640 | (2) | 706 | (2) | ||
| Distant metastasis | 201 | (5) | 1876 | (6) | 2077 | (6) | ||
| Missing | 3175 | (83) | 27,686 | (82) | 30,861 | (82) | ||
|
| ||||||||
| D’Amico risk groups *** | ||||||||
| Low | 429 | (11) | 3811 | (11) | 4240 | (11) | ||
| Intermediate | 1022 | (27) | 9369 | (28) | 10,391 | (28) | ||
| High | 2056 | (54) | 17,832 | (53) | 19,888 | (53) | ||
| Missing | 306 | (8) | 2702 | (8) | 3008 | (8) | ||
|
| ||||||||
| Presence of metastases **** | ||||||||
| M0 | 1080 | (28) | 10,551 | (31) | 11,631 | (31) | ||
| M+ | 572 | (15) | 4787 | (14) | 5359 | (14) | ||
| Mx | 2161 | (57) | 18,376 | (55) | 20,537 | (55) | ||
Suicide is defined as death with the following registered causes: ICD-10 codes X60–64 + Y87.0
Median follow-up time distribution based on the Kaplan-Meier method applied to the censored times reversing the roles of event status and censored.
Low risk: PSA <10 ng/ml (or missing PSA) and cT stage<T2c (or pre-TNM=”Localised”) and GS=6; Intermediate risk: PSA 10–20 ng/ml or cT stage=T2c or GS=7 (or pre-TNM=”locally advanced”); High risk: PSA>20 ng/ml or cT stage > cT2c (or pre-TNM=”Distant metastasis”) or GS>7.
M0: M-stage=M0 or pre-TNM=”Localized”; M+: M-stage=M+ or pre-TNM=”Distant metastasis”; Mx: M-stage=Mx or missing information on stage.